Henry Mugerwa

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · New England Journal of Medicine · 2021 · 179 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · The Lancet HIV · 2022 · 137 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

Cissy Kityo, Ivan Mambule, Joseph Musaazi et al. · The Lancet Infectious Diseases · 2024 · 96 citations · Full text

Medicine, Infectious Diseases, Pharmacology +12

Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated <i>Plasmodium falciparum</i> Malaria

E. Schmitt, Gilles Ndayisaba, Adoke Yeka et al. · Clinical Infectious Diseases · 2021 · 85 citations · Full text

Medicine, Infectious Diseases, Pharmacology +14

Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda

Sheila Kansiime, Doris M. Mwesigire, Henry Mugerwa · PLoS ONE · 2019 · 61 citations · Full text

Public Health, Health Sciences, Infectious Diseases +15